Beyond the Life Sciences Industrial Strategy with Sir John Bell
In 2017 the Government's Life Sciences Champion, Professor Sir John Bell, provided recommendations to government on the long term success of the life sciences sector. It was written in collaboration with industry, academia, charity, and research organisations.
The report considered seven core areas, namely Health Advanced Research Programme (HARP) proposal, reinforcing the UK science offer, growth and infrastructure, NHS collaboration, Data, Skills, and regulation.
In this session we will consider:
- What has made the life sciences industrial strategy a success?
- What else could be done to continue the success of the industrial strategy two years on?
- How can we assure the sustainability and growth of the life sciences industry beyond the industrial strategy?
Download the agenda here
Professor Sir John Bell GBE FRS is Regius Professor of Medicine at Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research. He served as President of the Academy of Medical Sciences (2006-2011). In December 2011, Sir John was appointed one of two UK Life Sciences Champions.
Tamsin joined the Civil Service 2007 after working at a blue chip consultancy and briefly at a think tank. Since then she has worked in a range of senior roles in the civil service in the Cabinet Office and Department of Health. She was the Head of Policy Projects at Public Health England, leading a portfolio of projects, including dementia prevention and health and social care integration. Following this she led the team supporting Sir Hugh Taylor to make his recommendations for the Accelerated Access Review and is now a Deputy Director at the Office for Life Sciences, a joint unit part of the Department of Health and Social care and the Department for Business Energy and Industrial Strategy.
Tamsin is in charge of the Life Sciences Industrial Strategy and Sector Policy team which supported Sir John Bell to write and publish the industry-led Life Sciences Industrial Strategy last summer and take this forward through the first ever sector deal as part of the Industrial Strategy White Paper. Her team is responsible for implementing the sector deal and working closely with industry to develop future policy and investment projects in line with the strategy.
Rt Hon Patricia Hewitt had a long and distinguished career in politics and government, serving as Secretary of State for Health (2005-2007), Secretary of State for Trade and Industry and Cabinet Minister for Women (2001-2005) in Tony Blair's Cabinet. Since leaving Parliament in 2010, she has had a portfolio career and is currently Chair of the Norfolk and Waveney Health and Care Partnership, leading the creation of an integrated carer system for over 1 million people; a senior adviser to FTI Consulting; and an advisory board member for Medefer, a digital health start-up. She also served for eight years as Chair of the UK India Business Council, promoting trade and investment between the two countries in healthcare and other sectors, and is now an adviser to the Board of Trade.
Tony Wood, SVP, Medicinal Science & Technology, joined GSK in October 2017. He is a member of the R&D Leadership Team, reporting to Hal Barron, President, R&D.
Tony was previously head of Worldwide Research & Development’s Medicinal Sciences at Pfizer, and prior to that held roles of increasing seniority in chemistry and medicinal sciences across a range of therapy areas. Tony played a leading role in the discovery of Maraviroc, a CCR5 antagonist for the treatment of HIV, and in recognition was awarded the RSC Malcolm Campbell Prize in 2005. He was also co-recipient of the ACS Heroes of Chemistry Prize, the Prix Galien USA and Scrip Awards in 2008, and the PhRMA Discoverers Award in 2010. In 2018 he was elected as a Fellow of the Academy of Medical sciences.
Tony is a named author and inventor on more than 50 publications and patents, and has represented the pharma view on UK funding council review boards, such as EPSRC and BBSRC.
Tony received his BSc and PhD in chemistry from the University of Newcastle upon Tyne, before completing post-doctoral studies with Professor Steven Ley, FRS at Imperial College in London. He continues to be a Visiting Professor at the University of Newcastle upon Tyne.